Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ: NMRA )

1.400 +0.020 (+1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,468,557
Open 1.380
Bid (Size) 1.370 (1)
Ask (Size) 1.440 (15)
Prev. Close 1.380
Today's Range 1.360 - 1.435
52wk Range 1.260 - 17.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire

Performance

YTD
-28.93%
-28.93%
1 Month
-16.17%
-16.17%
3 Month
-86.77%
-86.77%
6 Month
-88.17%
-88.17%
1 Year
-90.55%
-90.55%

More News

Read More
NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA)
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA)
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
NMRA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NMRA ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Via Benzinga
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Neumora Therapeutics, Inc. (NMRA) Investors: April 7, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
NMRA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Neumora Therapeutics, Inc. (NMRA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
NMRA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Neumora Therapeutics, Inc. (NMRA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
NMRA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 7, 2025 Deadline in Securities Fraud Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
NMRA Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 7, 2025 Deadline in Securities Fraud Class Action Lawsuit Against Neumora Therapeutics, Inc. (NMRA)
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
NMRA Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
NMRA Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc. (NMRA)
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
NMRA Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Shareholders of Deadline in Securities Fraud Class Action Lawsuit
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.